

ABSTRACT

The present disclosure relates to an immunoconjugate and the use thereof. In particular, the present disclosure relates to an immunoconjugate comprising a PD-1 antibody or an antigen-binding fragment thereof and IL-2, and the use of the immunoconjugate for

5 cancer treatment.